Tumor Necrosis Factor Receptor Superfamily Member 13B / CD267 (TNFRSF13B) Antibody (PE)
429€ (100 tests)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
Tumor Necrosis Factor Receptor Superfamily Member 13B / CD267 (TNFRSF13B) Antibody (PE)
Category
Primary Antibodies
Provider
Abbexa
Reference
abx140452
Tested Applications
FCM
Description
CD267 Antibody is a Rat Monoclonal against CD267.
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: Tumor Necrosis Factor Receptor Superfamily Member 13B / CD267 (TNFRSF13B) Immunogen: CD267-transfected RBL cells. |
| Host | Rat |
| Reactivity | Human |
| Detection Method | Laser Line: 550 Excitation/Emission: 565/575 |
| Recommended Dilution | FCM: 10 µl/100 µl of whole blood or 106 cells. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | PE |
| Isotype | IgG2a Kappa |
| Clone ID | J712 |
| Size 1 | 100 tests |
| Tested Applications | FCM |
| Buffer | Stabilizing PBS solution containing 15 mM sodium azide. |
| Availability | Shipped within 5-12 working days. |
| Storage | Store in the dark at 2-8°C. Avoid exposure to light. Do not freeze. |
| Dry Ice | No |
| UniProt ID | O14836 |
| Gene ID | 23495 |
| Alias | Tumor necrosis factor receptor superfamily member 13B,CVID,RYZN,TACI,CD267,CVID2,IGAD2,TNFRSF14B,Transmembrane activator and CAML interactor |
| Background | Antibody anti-TNFRSF13B |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
TNFRSF13B, also known as TACI (Transmembrane Activator and CAML Interactor), is a critical receptor in the immune system, specifically involved in B cell biology. TNFRSF13B belongs to the tumor necrosis factor receptor superfamily (TNFRSF) and plays an essential role in immune regulation by binding ligands such as APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor). These interactions are vital for B cell survival, proliferation, and differentiation, particularly in the context of generating long-lasting immune responses and maintaining immune homeostasis. Mutations in TNFRSF13B have been linked to various immunodeficiency disorders, such as Common Variable Immunodeficiency (CVID) and IgA deficiency. These conditions are associated with impaired antibody production, resulting in increased susceptibility to infections and autoimmune complications. Due to its importance in regulating immune responses, TNFRSF13B is studied intensively as a therapeutic target for both immunodeficiency disorders and autoimmune diseases where B cell activity is dysregulated.